Abstracts tagged "autoantigens"

Abstract Number: 2185 • ACR Convergence 2022
Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis
Anne-Renee van der Vuurst de Vries¹, Kathryn Hooper¹, Jonathan Graf², Katie Tuckwell¹ and Joshua Beilke¹, ¹Sonoma Biotherapeutics, South San Francisco, CA, ²Ucsf, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…
Abstract Number: 0256 • ACR Convergence 2022
Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires
Kevin Cunningham¹, Benjamin Hur², John Davis² and Jaeyun Sung², ¹University of Minnesota, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: RA is commonly diagnosed through a serological test for the presence of ACPA, and RA patients who test positive are collectively known as 'ACPA-positive…
Abstract Number: 0001 • ACR Convergence 2021
Autoantigenic Properties Indicated for the Entire Aminoacyl tRNA Synthetase Family in Idiopathic Inflammatory Myopathies
Charlotta Preger¹, Antonella Notarnicola¹, Cecilia Hellström², Edvard Wigren¹, Catia Cerqueira³, Peter Nilsson², Ingrid E Lundberg¹, Helena Persson⁴, Susanne Gräslund¹ and Per-Johan Jakobsson⁵, ¹Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ²Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, ³4Dcell, Montreuil, France, ⁴Drug Discovery and Development Platform, SciLifeLab & School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology (KTH), Solna, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoantibodies are thought to play a key role in the pathogenesis of idiopathic inflammatory myopathies (IIM). However, 40% of IIM patients, even those with…
Abstract Number: 0042 • ACR Convergence 2021
High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
Michael Richter¹, Hari Krishnamurthy², Sylvia Posso³, Jeffrey Carlin⁴ and Jane Buckner³, ¹University of Washington, Mercer Island, WA, ²Vibrant Sciences, San Carlos, CA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Antibodies to citrullinated and other modified proteins play a critical role in the pathogenesis of rheumatoid arthritis (RA). The prevalence and degree of multi-site…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
Abstract Number: 0713 • ACR Convergence 2021
MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients
Eveline Van Gompel¹, Catia Cerqueira², Karine Chemin³, Begum Horuluoglu¹, Angeles Shunashy Galindo-Feria⁴, khaled amara⁵, Edvard Wigren⁶, Susanne Gräslund⁶, Ellen De Langhe⁷, Olivier Benveniste⁸ and Ingrid E Lundberg⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²4Dcell, Montreuil, France, ³Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁷KU Leuven, Leuven, Belgium, ⁸UPMC, Paris, France
Background/Purpose: The presence of anti-melanoma differentiation associated protein 5 (MDA5) autoantibodies in myositis patients is associated with mucocutaneous ulcerations, (rapidly progressing) interstitial lung disease (RPILD),…
Abstract Number: 0720 • ACR Convergence 2021
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Yuto Izumi¹, Kazuki Hirano¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
Abstract Number: 1489 • ACR Convergence 2021
Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)
Yann BECKER¹, Jean-Philippe Gagné², Anne-Sophie Julien³, Tania Lévesque¹, Nadine Gougeard⁴, Vicente Rubio⁴, François-Michel Boisvert⁵, Dominique Jean⁶, Guy Poirier², Paul R Fortin⁷ and Éric Boilard¹, ¹Centre de Recherche ARThrite, Université Laval, Québec City, QC, Canada, ²Centre de Recherche du Centre Hospitalier Universitaire de Québec - Université Laval, Québec City, QC, Canada, ³Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁴Structural Enzymopathology Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain, ⁵Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, Canada, ⁷CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Mitochondria are organelles that possess several bacterial features such as a double-stranded genome with hypomethylated CpG islets, formylated proteins, and a double membrane composed…
Abstract Number: 1511 • ACR Convergence 2021
Investigation of Antigen Specific CD4+ T Cells in Patients with Idiopathic Inflammatory Myopathies
Begum Horuluoglu¹, Angeles Shunashy Galindo-Feria², Karine Chemin³, Genadiy Kozhukh⁴, Anatoly Dubnovitsky⁴, Vivianne Malmström⁵ and Ingrid E Lundberg⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) also known as myositis, are rare chronic autoimmune disorders represented by lesions in muscle, skin and lung. One of the…
Abstract Number: 1932 • ACR Convergence 2021
Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes
May Choi¹, Irene Chen², Ann Clarke³, Marvin Fritzler³, Katherine Buhler³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St.Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Francisco Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Dafna Gladman¹⁷, Ian N. Bruce¹⁸, Michelle Petri¹⁹, Ellen Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jnsen²⁴, Graciela Alarcn²⁵, Ronald van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁷, Guillermo Ruiz-Irastorza²⁸, S Sam Lim²⁹, Murat Inanc³⁰, Kenneth Kalunian³¹, Sren Jacobsen³², Christine Peschken³³, Diane Kamen³⁴, Anca Askanase³⁵, David Sontag² and Karen Costenbader³⁶, ¹Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ²Massachusetts Institute of Technology, Cambridge, MA, ³University of Calgary, Calgary, AB, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸University of Manchester, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰SUNY Downstate Health Sciences University, Brooklyn, NY, ²¹Raleigh Neurology Associates, Chapel Hill, NC, ²²Northwestern University, Chicago, IL, ²³Allegheny Health Network, Wexford, PA, ²⁴Lund University, Lund, Sweden, ²⁵University of Alabama at Birmingham, Birmingham, AL, ²⁶Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁹Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³⁰Istanbul University Faculty of Medicine, Istanbul, Turkey, ³¹UC San Diego, La Jolla, CA, ³²Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³³University of Manitoba, Winnipeg, MB, Canada, ³⁴Medical University of South Carolina, Charleston, SC, ³⁵Columbia University Medical Center, New York, NY, ³⁶Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Prior studies of SLE clusters based on autoantibodies have utilized cross-sectional data from single centers. We applied clustering techniques to longitudinal and comprehensive autoantibody…
Abstract Number: 0775 • ACR Convergence 2020
T and B Cell Responses to Common Tenascin-C Peptides in RA
JING Song¹, Anja Schwenzer², Sara Turcinov³, Alicia Wong², Cliff Rims¹, Lorena Rodriguez Martinez², David Arribas-Layton⁴, Christina Gerstner⁵, Virginia Muir⁶, Jeffrey Carlin⁷, Kim Midwood², Vivianne Malmström⁸, Eddie James¹ and Jane Buckner¹, ¹Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁴Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, ⁵Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, ⁸Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
Abstract Number: 0785 • ACR Convergence 2020
Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses
Austin Barry¹, Geoffrey Thiele¹, Ted Mikuls¹, Michael Duryee¹, Amy Nelson¹, Rohit Gaurav¹, Bryant England¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for comorbid chronic lung disease, with premature mortality. Therapies for RA-associated lung disease are…
Abstract Number: 1078 • ACR Convergence 2020
Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis
Antonella Notarnicola¹, Charlotta Preger², Susanna L. Lundström², Nuria Renard², Edvard Wigren², Eveline Van Gompel², Angeles S. Galindo-Feria², Helena Persson³, Maryam Fathi⁴, Johan Grunewald², Per-Johan Jakobsson², Susanne Gräslund², Ingrid Lundberg⁵ and Cátia Fernandes-Cerqueira², ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Karolinska Institutet, stockholm, Sweden, ³Science for Life Laboratories, KTH, Stockholm, Sweden, ⁴Karolinska University Hospital, stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine, Karolinska Institutet,, Stockholm, Sweden
Background/Purpose: To address the reactivity and affinity against histidyl-transfer RNA synthetase (HisRS) autoantigen of anti-Jo1 autoantibodies from serum and bronchoalveolar lavage fluid (BALF) and associations…
Abstract Number: 1440 • ACR Convergence 2020
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
Matthew Terrill¹, Hendrik Nel², Yassmin Musthaffa³, Wong Richard⁴, Ross Francis⁵, David Johnson⁵, Greg Keir⁶, David Gillis⁷ and Ranjeny Thomas⁸, ¹University of Queensland Diamantina Institute and Princess Alexandra Hospital, Rheumatology Department, Brisbane- Australia, Moffat beach, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ³University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Immunology Department, Princess Alexandra Hospital, Brisbane- Australia, Brisbane, Australia, ⁵Renal Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁶Respiratory Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁷Immunopathology Department, Royal Women’s and Children’s Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁸University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: In Myeloperoxidase (MPO) Anti Neutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (MPO-AAV), murine and human studies suggest that the MPO435-465 region, which includes ANCA-binding MPO447-459, the…
Abstract Number: 2044 • ACR Convergence 2020
Complex, Dynamic Attributes of Antigen-specific T Cells in Rheumatoid Arthritis
Eddie James¹, Virginia Muir², Cliff Rims¹, Hannes Uchtenhagen³, Anne Hocking³, Sylvia Posso³, Heather Bukiri⁴, Jeffrey Carlin⁴, Bernard Ng⁵, Peter Linsley³ and Jane Buckner¹, ¹Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA, ⁵VA Puget Sound Health Care System, Seattle, WA
Background/Purpose: CD4+ T cells are implicated in the pathogenesis of rheumatoid arthritis (RA) due to strong genetic association with HLA class II alleles, the presence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].